StockMacro
Company, fund or insider

Help

Menu

Aligos Therapeutics

$1.22 -79% in 6 monthsMarket cap $7.6M

ALGS on XNAS, Health Care, Aligos Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 85% in 12 months to $1.22 while cash of $31.1M sits above a $7.8M market cap.

  • BadShort interest at 698K shares, 2.4 times a year earlier
  • BadNet loss of $66.3M against $5.8M revenue, up 122%

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
82
Website
aligos.com
Listed
Nasdaq, US
Last results
6 Nov 2026
Next results
expected around 4 Mar 2027 (an estimate: a year ago it reported on 5 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.8M, net loss $21.9M.
Quarter to 31 Dec 2021: revenue –, net income -$37.7MQuarter to 31 Mar 2022: revenue –, net income -$35.6MQuarter to 30 Jun 2022: revenue $0, net income -$19.9MQuarter to 30 Jun 2022: revenue $0, net income -$19.9MQuarter to 30 Sep 2022: revenue $0, net income -$18.6MQuarter to 30 Sep 2022: revenue $0, net income -$18.6MQuarter to 31 Dec 2022: revenue $0, net income -$21.9MQuarter to 31 Dec 2022: revenue $0, net income -$21.9MQuarter to 31 Mar 2023: revenue $140K, net income -$23.0MQuarter to 31 Mar 2023: revenue $140K, net income -$23.0MQuarter to 30 Jun 2023: revenue $4.3M, net income -$18.8MQuarter to 30 Jun 2023: revenue $4.3M, net income -$18.8MQuarter to 30 Sep 2023: revenue $1.1M, net income -$18.0MQuarter to 30 Sep 2023: revenue $1.1M, net income -$18.0MQuarter to 31 Dec 2023: revenue $672K, net income -$27.9MQuarter to 31 Dec 2023: revenue $672K, net income -$27.9MQuarter to 31 Mar 2024: revenue $694K, net income -$34.9MQuarter to 31 Mar 2024: revenue $694K, net income -$34.9MQuarter to 30 Jun 2024: revenue $1.1M, net income $5.1MQuarter to 30 Jun 2024: revenue $1.1M, net income $5.1MQuarter to 30 Sep 2024: revenue $1.2M, net income -$19.3MQuarter to 30 Sep 2024: revenue $1.2M, net income -$19.3MQuarter to 31 Dec 2024: revenue $606K, net income -$82.2MQuarter to 31 Dec 2024: revenue $606K, net income -$82.2MQuarter to 31 Mar 2025: revenue $311K, net income $43.1MQuarter to 31 Mar 2025: revenue $311K, net income $43.1MQuarter to 30 Jun 2025: revenue $965K, net income -$15.9MQuarter to 30 Jun 2025: revenue $965K, net income -$15.9MQuarter to 30 Sep 2025: revenue $741K, net income -$31.5MQuarter to 30 Sep 2025: revenue $741K, net income -$31.5MQuarter to 31 Dec 2025: revenue $169K, net income -$19.9MQuarter to 31 Dec 2025: revenue $169K, net income -$19.9MQuarter to 31 Mar 2026: revenue $2.8M, net income -$23.0MQuarter to 31 Mar 2026: revenue $2.8M, net income -$23.0MQuarter to 30 Jun 2026: revenue $0, net income -$1.5MQuarter to 30 Jun 2026: revenue $0, net income -$1.5MQuarter to 30 Sep 2026: revenue $2.8M, net income -$21.9MQuarter to 30 Sep 2026: revenue $2.8M, net income -$21.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $82.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$2.8M-$21.9M
30 Jun 2026$0-$1.5M
31 Mar 2026$2.8M-$23.0M
31 Dec 2025$169K-$19.9M
30 Sep 2025$741K-$31.5M
30 Jun 2025$965K-$15.9M
31 Mar 2025$311K$43.1M
31 Dec 2024$606K-$82.2M
30 Sep 2024$1.2M-$19.3M
30 Jun 2024$1.1M$5.1M
31 Mar 2024$694K-$34.9M
31 Dec 2023$672K-$27.9M
30 Sep 2023$1.1M-$18.0M
30 Jun 2023$4.3M-$18.8M
31 Mar 2023$140K-$23.0M
31 Dec 2022$0-$21.9M
30 Sep 2022$0-$18.6M
30 Jun 2022$0-$19.9M
31 Mar 2022–-$35.6M
31 Dec 2021–-$37.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $5.8M $2.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +122% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$66.3M -$86.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -159% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $31.1M $99.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$31.1M (net cash) -$99.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.67 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Aligos TherapeuticsALGS (this company) $7.6Mloss1.3+122%–
Black Hawk AcquisitionBKHA $7.7M5.9–––
Intensity TherapeuticsINTS $8.2Mloss–––
IN8bioINAB $8.2Mloss–––
Jasper TherapeuticsJSPR $9.6Mloss–––
aTyr PharmaATYR $9.7Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+16%

36 13F filers vs 31

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

677K shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

20.8

677K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-4.3%

707K shares sold short in the report before, 677K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

62%

62% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$220K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

10

10 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

10×

10 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 698K, 2.4× a year earlier

Price $1.22 on 20 Nov 2026, -85% over 12 months (12-month range $1.22 to $13.29)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $2.8M in the latest quarter, +282% on a year earlier.
Capital spending per quarter. Capital spending $7K in the latest quarter, -99% on a year earlier.
Institutional holders (13F filers). 36 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.
Lobbying spend. Lobbying spend: $220K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
27 Oct 2026Sharp changeShort interest spike: short interest spike, 707K vs usual 301K (2026-10-15); 3.0x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 709K vs usual 294K (2026-09-30); 2.6x the same period a year earlier
29 Sep 2026Sharp changeShort interest spike: short interest spike, 698K vs usual 293K (2026-09-15); 2.4x the same period a year earlier
15 Sep 2026Sharp changeShort interest spike: short interest spike, 649K vs usual 293K (2026-08-31); 2.1x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 568K vs usual 293K (2026-08-14); 1.9x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 607K vs usual 293K (2026-07-31); 1.7x the same period a year earlier
26 Jun 20268-K and other filingsDirector or officer change
26 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jun 2026Sharp changeShort interest spike: short interest spike, 577K vs usual 293K (2026-05-29); 1.0x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 535K vs usual 293K (2026-05-15); 0.8x the same period a year earlier
4 Feb 20268-K and other filingsDirector or officer change
4 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Jun 20258-K and other filingsDirector or officer change
26 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Feb 20258-K and other filingsPrivate placement of securities (Form D)
3 Feb 20258-K and other filingsDirector or officer change
3 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Aug 20248-K and other filingsDirector or officer change
16 Jul 2024Sharp changeShort interest spike: short interest spike, 2.2M vs usual 771K (2024-06-28); 2.6x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 1.9M vs usual 771K (2024-06-14); 2.4x the same period a year earlier
28 Jun 20248-K and other filingsDirector or officer change
18 Jun 2024Sharp changeShort interest spike: short interest spike, 1.9M vs usual 771K (2024-05-31); 2.0x the same period a year earlier
31 May 20248-K and other filingsDelisting notice or listing transfer
28 May 2024Sharp changeShort interest spike: short interest spike, 1.1M vs usual 763K (2024-05-15); 1.5x the same period a year earlier
22 May 20248-K and other filingsDirector or officer change
22 May 20248-K and other filingsDelisting notice or listing transfer
15 May 20248-K and other filingsDirector or officer change
28 Feb 20248-K and other filingsDirector or officer change
28 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Nov 20238-K and other filingsDirector or officer change
15 Nov 20238-K and other filingsDirector or officer change
15 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Nov 20238-K and other filingsPrivate placement of securities (Form D)
24 Sep 2023Sharp changeFirst federal award: first federal award: ALIGOS THERAPEUTICS INC: new Department of Health and Human Services contract 75N93023C00052 ($8,469,477)
7 Sep 20238-K and other filingsDelisting notice or listing transfer
9 Mar 2023Lobbying filingnew lobbying registration (WILMER CUTLER PICKERING HALE AND DORR LLP)
9 Mar 2023Sharp changeFirst lobbying registration: first lobbying registration: ALIGOS THERAPEUTICS, INC.: new lobbying registration (WILMER CUTLER PICKERING HALE AND DORR LLP)
14 Jun 2022Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.9M (2022-05-31); 1.9x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.9M (2022-05-13); 1.8x the same period a year earlier
Insider net buying (open market)
Month from 1 Oct 2023: $6.0M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 30 Jun 2022: $0; public on 4 Aug 2023
Quarter ended 30 Sep 2022: $0; public on 3 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $140K; public on 5 May 2023
Quarter ended 30 Jun 2023: $4.3M; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $1.1M; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $672K; public on 13 Mar 2024
Quarter ended 31 Mar 2024: $694K, +396% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $1.1M, -75% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $1.2M, +15% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $606K, -9.8% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $311K, -55% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $965K, -9.0% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $741K, -41% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $169K, -72% on a year earlier; public on 6 Mar 2026
Quarter ended 31 Mar 2026: $2.8M, +810% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $2.8M, +282% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $336K, +451% on a year earlier; public on 11 Mar 2022
Quarter ended 31 Mar 2022: $515K, +68% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $334K, +120% on a year earlier; public on 5 Aug 2022
Quarter ended 31 Dec 2022: $91K, -73% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $7K, -99% on a year earlier; public on 5 May 2023
Institutional holders (13F filers)
31 Dec 2021 report: 67; public on 14 Feb 2022
31 Mar 2022 report: 74; public on 16 May 2022
30 Jun 2022 report: 60; public on 15 Aug 2022
30 Sep 2022 report: 50; public on 14 Nov 2022
31 Dec 2022 report: 38; public on 14 Feb 2023
31 Mar 2023 report: 43; public on 15 May 2023
30 Jun 2023 report: 40; public on 14 Aug 2023
30 Sep 2023 report: 34; public on 14 Nov 2023
31 Dec 2023 report: 40; public on 14 Feb 2024
31 Mar 2024 report: 49; public on 15 May 2024
30 Jun 2024 report: 47; public on 14 Aug 2024
30 Sep 2024 report: 27; public on 14 Nov 2024
31 Dec 2024 report: 34; public on 14 Feb 2025
31 Mar 2025 report: 35; public on 15 May 2025
30 Jun 2025 report: 35; public on 14 Aug 2025
30 Sep 2025 report: 32; public on 14 Nov 2025
31 Dec 2025 report: 40; public on 17 Feb 2026
31 Mar 2026 report: 34; public on 15 May 2026
30 Jun 2026 report: 31; public on 14 Aug 2026
30 Sep 2026 report: 36; public on 16 Nov 2026
Federal obligations
Month from 1 Sep 2023: $8.5M published
Month from 1 Apr 2024: $1.3M published
Month from 1 Jul 2024: $0 published
Month from 1 Apr 2025: $1.5M published
Month from 1 Jun 2025: $0 published
Lobbying spend
Quarter from 1 Apr 2023: $110K published
Quarter from 1 Jul 2023: $110K published
Quarter from 1 Jan 2026: $80K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $60K published

What is unusual now

  • Made public in the last 90 days: it had 698K shares sold short in the 15 Sep 2026 report, 2.4× the same report last year; it also had 709K shares sold short in the 30 Sep 2026 report, 2.6× the same report last year. 5 sharp changes in all.
  • Short interest spike: had 607K shares sold short in the 31 Jul 2026 report, 1.7× the same report last year Public on 12 Aug 2026.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 5 insider trades

No trades in the last 90 days; the latest was filed 27 Oct 2023. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
27 Oct 2023Carole NuechterleinDirector, 10% ownerBuy7,933,601$0.76$6.0MForm 4
22 Oct 2020Novo Holdings A/S10% ownerBuy200,000$15.00$3.0MForm 4
20 Oct 2020Versant Venture Capital VI, L.P. and 1 other10% ownerBuy200,000$15.00$3.0MForm 4
20 Oct 2020Vivo Capital Surplus Fund VIII, L.P. and 2 others10% ownerBuy550,000$15.00$8.2MForm 4

36 institutions reported shares at the end of Q3 2026, 6% of the shares outstanding; 10 opened a position, 5 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Deep Track Capital, LP444K1.04%$2.5MNo change
Sio Capital Management, LLC327K0.77%$1.8MNo change
Parkman Healthcare Partners LLC326K0.76%$1.8MNew+326K
Marshall Wace, LLP247K0.58%$1.4MNo change
Schonfeld Strategic Advisors LLC182K0.43%$1.0MNew+182K
Woodline Partners LP177K0.42%$999KNo change
Vanguard Capital Management LLC176K0.41%$988KNo change
Baker Bros. Advisors LP83K0.19%$468KNo change
HHLR Advisors, Ltd.76K0.18%$429KNo change
D. E. Shaw & Co., Inc.72K0.17%$403K+5,065+7.6%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 18 Sep 2023. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
18 Sep 2023Department of Health and Human ServicesNational Institutes of Health$8.5MTO CONDUCT CLINICAL DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19.USAspending

Company events

All 26 company events

In 12 months: 2 director or officer changes, 2 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
15 Sep 2026Signed a major agreement8-K
26 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
21 Apr 2026Signed a major agreement8-K
4 Feb 2026Director or officer change8-K
26 Jun 2025Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
28 Feb 2025Private placement of securities (Form D)$105.0M sold of $105.0M offeredD
12 Feb 2025Signed a major agreementSame filing: sold shares privately8-K
3 Feb 2025Director or officer change8-K

Reported lobbying spend: $60K in Q2 2026, $80K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
24 Jan 2023NewWilmer Cutler Pickering Hale And Dorr LLPfor Aligos Therapeutics, Inc.Competition IssuesLaborFiling

The 5 newest of 68 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 27 Oct 2026Short interest and volume change

    had 707K shares sold short in the 15 Oct 2026 report, 3.0× the same report last year.

    Same report last year: 235K; its normal report is 301K.

    See the evidence
    This period
    707K (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    301K
    Typical spread (median absolute deviation)
    74K
    How far from its usual level
    +3.7
    Same report last year
    235K
    History used
    2,176 days
    2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K2026-05-29: 577K2026-06-15: 612K2026-06-30: 543K2026-07-15: 521K2026-07-31: 607K2026-08-14: 568K2026-08-31: 649K2026-09-15: 698K2026-09-30: 709K2026-10-15: 707K
    the 15 Oct 2026 report24 earlier reportsnormal: 301K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 10 Oct 2026Short interest and volume change

    had 709K shares sold short in the 30 Sep 2026 report, 2.6× the same report last year.

    Same report last year: 273K; its normal report is 294K.

    See the evidence
    This period
    709K (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    294K
    Typical spread (median absolute deviation)
    64K
    How far from its usual level
    +4.4
    Same report last year
    273K
    History used
    2,161 days
    2025-09-30: 273K2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K2026-05-29: 577K2026-06-15: 612K2026-06-30: 543K2026-07-15: 521K2026-07-31: 607K2026-08-14: 568K2026-08-31: 649K2026-09-15: 698K2026-09-30: 709K
    the 30 Sep 2026 report24 earlier reportsnormal: 294K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 25 Sep 2026Short interest and volume change

    had 698K shares sold short in the 15 Sep 2026 report, 2.4× the same report last year.

    Same report last year: 292K; its normal report is 293K.

    See the evidence
    This period
    698K (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    293K
    Typical spread (median absolute deviation)
    59K
    How far from its usual level
    +4.6
    Same report last year
    292K
    History used
    2,146 days
    2025-09-15: 292K2025-09-30: 273K2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K2026-05-29: 577K2026-06-15: 612K2026-06-30: 543K2026-07-15: 521K2026-07-31: 607K2026-08-14: 568K2026-08-31: 649K2026-09-15: 698K
    the 15 Sep 2026 report24 earlier reportsnormal: 293K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 11 Sep 2026Short interest and volume change

    had 649K shares sold short in the 31 Aug 2026 report, 2.1× the same report last year.

    Same report last year: 312K; its normal report is 293K.

    See the evidence
    This period
    649K (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    293K
    Typical spread (median absolute deviation)
    55K
    How far from its usual level
    +4.3
    Same report last year
    312K
    History used
    2,131 days
    2025-08-29: 312K2025-09-15: 292K2025-09-30: 273K2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K2026-05-29: 577K2026-06-15: 612K2026-06-30: 543K2026-07-15: 521K2026-07-31: 607K2026-08-14: 568K2026-08-31: 649K
    the 31 Aug 2026 report24 earlier reportsnormal: 293K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 26 Aug 2026Short interest and volume change

    had 568K shares sold short in the 14 Aug 2026 report, 1.9× the same report last year.

    Same report last year: 303K; its normal report is 293K.

    See the evidence
    This period
    568K (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    293K
    Typical spread (median absolute deviation)
    44K
    How far from its usual level
    +4.3
    Same report last year
    303K
    History used
    2,114 days
    2025-08-15: 303K2025-08-29: 312K2025-09-15: 292K2025-09-30: 273K2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K2026-05-29: 577K2026-06-15: 612K2026-06-30: 543K2026-07-15: 521K2026-07-31: 607K2026-08-14: 568K
    the 14 Aug 2026 report24 earlier reportsnormal: 293K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 12 Aug 2026Short interest and volume change

    had 607K shares sold short in the 31 Jul 2026 report, 1.7× the same report last year.

    Same report last year: 362K; its normal report is 293K.

    See the evidence
    This period
    607K (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    293K
    Typical spread (median absolute deviation)
    44K
    How far from its usual level
    +4.9
    Same report last year
    362K
    History used
    2,100 days
    2025-07-31: 362K2025-08-15: 303K2025-08-29: 312K2025-09-15: 292K2025-09-30: 273K2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K2026-05-29: 577K2026-06-15: 612K2026-06-30: 543K2026-07-15: 521K2026-07-31: 607K
    the 31 Jul 2026 report24 earlier reportsnormal: 293K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 26 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 26 Jun 2026Filings record

    Director or officer change

  9. 10 Jun 2026Short interest and volume change

    had 577K shares sold short in the 29 May 2026 report, 1.0× the same report last year.

    Same report last year: 553K; its normal report is 293K.

    See the evidence
    This period
    577K (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    293K
    Typical spread (median absolute deviation)
    44K
    How far from its usual level
    +4.4
    Same report last year
    553K
    History used
    2,037 days
    2025-05-30: 553K2025-06-13: 542K2025-06-30: 533K2025-07-15: 392K2025-07-31: 362K2025-08-15: 303K2025-08-29: 312K2025-09-15: 292K2025-09-30: 273K2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K2026-05-29: 577K
    the 29 May 2026 report24 earlier reportsnormal: 293K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 28 May 2026Short interest and volume change

    had 535K shares sold short in the 15 May 2026 report, 16% below the same report last year.

    Same report last year: 640K; its normal report is 293K.

    See the evidence
    This period
    535K (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    293K
    Typical spread (median absolute deviation)
    44K
    How far from its usual level
    +3.8
    Same report last year
    640K
    History used
    2,023 days
    2025-05-15: 640K2025-05-30: 553K2025-06-13: 542K2025-06-30: 533K2025-07-15: 392K2025-07-31: 362K2025-08-15: 303K2025-08-29: 312K2025-09-15: 292K2025-09-30: 273K2025-10-15: 235K2025-10-31: 227K2025-11-14: 234K2025-11-28: 226K2025-12-15: 258K2025-12-31: 241K2026-01-15: 269K2026-01-30: 294K2026-02-13: 289K2026-02-27: 290K2026-03-13: 295K2026-03-31: 306K2026-04-15: 276K2026-04-30: 490K2026-05-15: 535K
    the 15 May 2026 report24 earlier reportsnormal: 293K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 4 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 4 Feb 2026Filings record

    Director or officer change

  13. 26 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 26 Jun 2025Filings record

    Director or officer change

  15. 28 Feb 2025Filings record

    Private placement of securities (Form D)

  16. 3 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 3 Feb 2025Filings record

    Director or officer change

  18. 8 Aug 2024Filings record

    Director or officer change

  19. 11 Jul 2024Short interest and volume change

    had 2.2M shares sold short in the 28 Jun 2024 report, 2.6× the same report last year.

    Same report last year: 818K; its normal report is 771K.

    See the evidence
    This period
    2.2M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    771K
    Typical spread (median absolute deviation)
    68K
    How far from its usual level
    +13.6
    Same report last year
    818K
    History used
    1,337 days
    2023-06-30: 818K2023-07-14: 803K2023-07-31: 777K2023-08-15: 742K2023-08-31: 761K2023-09-15: 765K2023-09-29: 753K2023-10-13: 761K2023-10-31: 735K2023-11-15: 725K2023-11-30: 757K2023-12-15: 864K2023-12-29: 855K2024-01-12: 840K2024-01-31: 894K2024-02-15: 317K2024-02-29: 369K2024-03-15: 366K2024-03-28: 869K2024-04-15: 657K2024-04-30: 838K2024-05-15: 1.1M2024-05-31: 1.9M2024-06-14: 1.9M2024-06-28: 2.2M
    the 28 Jun 2024 report24 earlier reportsnormal: 771K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 28 Jun 2024Filings record

    Director or officer change

  21. 27 Jun 2024Short interest and volume change

    had 1.9M shares sold short in the 14 Jun 2024 report, 2.4× the same report last year.

    Same report last year: 786K; its normal report is 771K.

    See the evidence
    This period
    1.9M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    771K
    Typical spread (median absolute deviation)
    57K
    How far from its usual level
    +12.8
    Same report last year
    786K
    History used
    1,323 days
    2023-06-15: 786K2023-06-30: 818K2023-07-14: 803K2023-07-31: 777K2023-08-15: 742K2023-08-31: 761K2023-09-15: 765K2023-09-29: 753K2023-10-13: 761K2023-10-31: 735K2023-11-15: 725K2023-11-30: 757K2023-12-15: 864K2023-12-29: 855K2024-01-12: 840K2024-01-31: 894K2024-02-15: 317K2024-02-29: 369K2024-03-15: 366K2024-03-28: 869K2024-04-15: 657K2024-04-30: 838K2024-05-15: 1.1M2024-05-31: 1.9M2024-06-14: 1.9M
    the 14 Jun 2024 report24 earlier reportsnormal: 771K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 12 Jun 2024Short interest and volume change

    had 1.9M shares sold short in the 31 May 2024 report, 2.0× the same report last year.

    Same report last year: 917K; its normal report is 771K.

    See the evidence
    This period
    1.9M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    771K
    Typical spread (median absolute deviation)
    57K
    How far from its usual level
    +12.8
    Same report last year
    917K
    History used
    1,309 days
    2023-05-31: 917K2023-06-15: 786K2023-06-30: 818K2023-07-14: 803K2023-07-31: 777K2023-08-15: 742K2023-08-31: 761K2023-09-15: 765K2023-09-29: 753K2023-10-13: 761K2023-10-31: 735K2023-11-15: 725K2023-11-30: 757K2023-12-15: 864K2023-12-29: 855K2024-01-12: 840K2024-01-31: 894K2024-02-15: 317K2024-02-29: 369K2024-03-15: 366K2024-03-28: 869K2024-04-15: 657K2024-04-30: 838K2024-05-15: 1.1M2024-05-31: 1.9M
    the 31 May 2024 report24 earlier reportsnormal: 771K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 31 May 2024Filings record

    Delisting notice or listing transfer

  24. 25 May 2024Short interest and volume change

    had 1.1M shares sold short in the 15 May 2024 report, 1.5× the same report last year.

    Same report last year: 734K; its normal report is 763K.

    See the evidence
    This period
    1.1M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    763K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +4.4
    Same report last year
    734K
    History used
    1,293 days
    2023-05-15: 734K2023-05-31: 917K2023-06-15: 786K2023-06-30: 818K2023-07-14: 803K2023-07-31: 777K2023-08-15: 742K2023-08-31: 761K2023-09-15: 765K2023-09-29: 753K2023-10-13: 761K2023-10-31: 735K2023-11-15: 725K2023-11-30: 757K2023-12-15: 864K2023-12-29: 855K2024-01-12: 840K2024-01-31: 894K2024-02-15: 317K2024-02-29: 369K2024-03-15: 366K2024-03-28: 869K2024-04-15: 657K2024-04-30: 838K2024-05-15: 1.1M
    the 15 May 2024 report24 earlier reportsnormal: 763K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 22 May 2024Filings record

    Director or officer change

  26. 22 May 2024Filings record

    Delisting notice or listing transfer

  27. 15 May 2024Filings record

    Director or officer change

  28. 28 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 28 Feb 2024Filings record

    Director or officer change

  30. 22 Nov 2023Filings record

    Director or officer change

  31. 15 Nov 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 15 Nov 2023Filings record

    Director or officer change

  33. 7 Nov 2023Filings record

    Private placement of securities (Form D)

  34. 28 Oct 2023Insiders record

    Nuechterlein Carole (director) bought 7,933,601 shares of ALGS ($6.0M) (dated 27 Oct 2023)

  35. 24 Sep 2023Government contracts change

    won its first federal award in our data, a $8.5M Department of Health and Human Services contract.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  36. 24 Sep 2023Government contracts record

    ALIGOS THERAPEUTICS INC: new Department of Health and Human Services contract 75N93023C00052 ($8.5M) (dated 18 Sep 2023)

  37. 7 Sep 2023Filings record

    Delisting notice or listing transfer

  38. 9 Mar 2023Lobbying change

    registered for federal lobbying for the first time in our data (Wilmer Cutler Pickering Hale And Dorr Llp).

    See the evidence (1 source record)
    Source coverage starts
    2 Jul 2009
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  39. 9 Mar 2023Lobbying record

    ALIGOS THERAPEUTICS, INC.: new lobbying registration (WILMER CUTLER PICKERING HALE AND DORR LLP) (dated 24 Jan 2023)

  40. 10 Jun 2022Short interest and volume change

    had 3.0M shares sold short in the 31 May 2022 report, 1.9× the same report last year.

    Same report last year: 1.6M; its normal report is 1.9M.

    See the evidence
    This period
    3.0M (the 31 May 2022 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    188K
    How far from its usual level
    +3.7
    Same report last year
    1.6M
    History used
    578 days
    2021-05-14: 1.6M2021-05-28: 1.6M2021-06-15: 1.6M2021-06-30: 1.7M2021-07-15: 1.8M2021-07-30: 1.8M2021-08-13: 1.9M2021-08-31: 1.8M2021-09-15: 1.7M2021-09-30: 1.9M2021-10-15: 1.9M2021-10-29: 2.0M2021-11-15: 1.9M2021-11-30: 2.1M2021-12-15: 2.2M2022-01-14: 1.9M2022-01-31: 2.0M2022-02-15: 2.1M2022-02-28: 2.1M2022-03-15: 2.2M2022-03-31: 2.3M2022-04-14: 2.4M2022-04-29: 2.6M2022-05-13: 2.9M2022-05-31: 3.0M
    the 31 May 2022 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 54 entries; narrow the window or the kind of data to see older ones.

Not listed: 62 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001799448
Ticker
ALGS
Domain
aligos.com
Employer name
Aligos Therapeutics, Inc. (1 unverified)
Hq location
CA|SOUTH SAN FRANCISCO|94080 (1 unverified)
Lobbying client
aligos therapeutics
Name
Aligos Therapeutics, Inc.
Uei
ED19ABDRLV29
  • DOL H-1B labor condition applications and PERM certifications21 data points13 Jun 2022 to 6 Jul 2026
  • Federal lobbying disclosures (LDA)1 record, 35 data points24 Jan 2023 to 30 Sep 2026
  • SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)84 records16 Jan 2020 to 6 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)407 data points31 Dec 2018 to 30 Sep 2026
  • SEC Form 4 insider transactions5 records, 12 data points20 Oct 2020 to 27 Oct 2023
  • FINRA short interest (twice monthly)431 data points30 Oct 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3064 data points16 Oct 2020 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 15 data points18 Sep 2023 to 18 Jun 2025